加州資源 CRC 深 滬
等待開盤 08-21 09:30:00 美东时间
47.72
+0.340
+0.72%
華盛通- 最 高48.15
- 今 開48.02
- 成交量 80.02万股
- 最 低 47.16
- 昨 收 47.38
- 總市值 39.93亿
- 52周最高 59.2475
- 市盈率 靜 10.33
- 換手率 0.96%
- 52周最低 30.5825
- 委 比 -50.00%
- 總股本 8368.00万
- 歷史最高 59.2475
- 量 比 1.06
- 振 幅 2.09%
- 歷史最低 -4.009
- 每 手 1
- 風險率 5.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What Analysts Are Saying About California Resources Stock
In the last three months, 8 analysts have published ratings on California Resou...
今天 03:01
UBS Maintains Buy on California Resources, Raises Price Target to $63
UBS analyst Josh Silverstein maintains California Resources (NYSE:CRC) with a Buy and raises the price target from $61 to $63.
今天 02:09
Agilent, Bristol Myers win FDA nod for cancer diagnostic test
Agilent (NYSE:A) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its Dako Omnis test developed with Bristol Myers Squibb (NYSE:BMY) as a companion diagnostic to id...
08-20 23:31
Agenus to Host Aug. 27 Virtual Briefing Highlighting Cancer Drug Pipeline and Phase 3 CRC Study
Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET. The event will feature presentations from
08-19 19:33
国金医药甘坛焕丨创新药前瞻深度：从IL-2双抗，看TAA、细胞及趋化因子的PD-1升级新方向
（来源：国金证券研究所） 作者：甘坛焕、赵海春 摘要 背景 创新药BD（授权合作交易）及其首付额爆发，下一个十亿美元首付花落谁家成市场新焦点。（...
08-14 07:34
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Marathon, others see new opportunity in California as regulatory policy eases
As competitors close California refineries, Marathon Petroleum (NYSE:MPC) said this week it expects to benefit from greater access to in-state crudes and sending fuel to the wider West Coast region fr...
08-10 08:45
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.
08-08 22:55
Mizuho Maintains Outperform on California Resources, Raises Price Target to $64
Mizuho analyst Nitin Kumar maintains California Resources (NYSE:CRC) with a Outperform and raises the price target from $61 to $64.
08-08 20:09
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a major strategic move.
08-08 02:56
